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Summary
Background.  —  Atrial  ﬁbrillation  is  the  main  cause  of  stroke,  but  the  risk  can  be  reduced,  usually
with vitamin  K  antagonists  (VKAs)  such  as  warfarin.  The  RE-LY  atrial  ﬁbrillation  study  demon-
strated that  the  rates  of  stroke  and  systemic  embolism  with  dabigatran  (an  oral  direct  thrombin
inhibitor)  were  similar  to  or  lower  than  those  with  warfarin.
Aims. —  To  estimate  the  cost-effectiveness,  from  a  French  payer  perspective,  of  dabigatran
(150 or  110  mg  bid  for  patients  <  or  ≥  80  years,  respectively)  versus  warfarin.
Methods.  —  Cost-effectiveness  was  modeled  using  a  Markov  model  in  a  cohort  of  10,000  patients
with atrial  ﬁbrillation  followed  over  their  lifetime.  Events  accounted  for  included  ischemic
stroke, systemic  embolism,  transient  ischemic  attack,  hemorrhage,  myocardial  infarction  and
Abbreviations: bid, bis in die; DRG, diagnosis-related group; EPHAD, Établissement d’hébergement pour personnes agées dépendantes
(nursing home for dependent elderly people); HAS, Haute Autorité de santé (French National Authority for Health); ICD-10, 10th revision
of the International Statistical Classiﬁcation of Diseases and Related Health Problems; ICER, Incremental Cost-Effectiveness Ratio; INR,
International Normalized Ratio; NSF, National Sickness Fund; PMSI, Programme de médicalisation des sytèmes d’information (French National
Hospital Database); QALY, quality-adjusted life Year; RR, relative risk; USLD, unité de soins longue durée (long-term care unit); VKA, vitamin
K antagonist.
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death.  The  model  patient  population  matched  the  RE-LY  patients.  Dabigatran  was  compared
with ‘‘trial-like’’  warfarin  and  ‘‘real-world’’  prescribing.  Risks  of  clinical  events  were  obtained
from RE-LY.  Event  and  follow-up  costs  were  based  on  the  French  national  tariff  or  published
literature.  Clinical  events,  QALYs,  total  costs  and  incremental  cost-effectiveness  ratios  (ICERs)
were calculated.
Results.  —  The  ICERs  of  dabigatran  compared  with  ‘‘trial-like’’  warfarin  and  ‘‘real-world’’
prescribing  were  D15,838/QALY  and  D7473/QALY,  respectively.  Deterministic  and  probabilis-
tic sensitivity  analyses  showed  these  to  be  robust  to  uncertainty  and  variability  in  the  model
parameters.  The  ICER  for  dabigatran  was  below  D24,000/QALY  or  D36,000/QALY  in  71%  or  92%,
respectively,  of  the  simulations  when  compared  with  ‘‘trial-like’’  warfarin  and  100%  and  100%,
respectively,  when  compared  with  ‘‘real-world’’  prescribing.
Conclusion.  —  This  study  suggests  that  the  use  of  dabigatran  in  French  atrial  ﬁbrillation  patients
is cost-effective,  according  to  usually  accepted  thresholds.
© 2014  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  La  ﬁbrillation  auriculaire  est  la  principale  cause  d’accident  vasculaire  cérébral,
mais le  risque  peut  être  diminué,  principalement  avec  des  antivitamines  K  (AVK)  tels  que  la
warfarin. L’étude  RE-LY  a  démontré  que  les  taux  d’AVC  et  d’embolie  systémique  avec  dabigatran
étaient similaires  ou  inférieurs  à  ceux  observés  chez  des  patients  traités  par  warfarine  (AVK).
Objectif.  —  Estimer  le  coût-efﬁcacité,  dans  une  perspective  payeur,  de  dabigatran  (150  mg  ou
110 mg  deux  fois  par  jour  chez  les  patients  âgés  de  moins  et  de  plus  de  80  ans,  respectivement)
versus warfarin.
Méthodes.  —  Le  coût-efﬁcacité  a  été  modélisé  à  l’aide  d’un  modèle  de  Markov  appliqué  à  une
cohorte de  10  000  patients  présentant  une  ﬁbrillation  jusqu’au  décès.  Les  événements  clin-
iques pris  en  compte  étaient  :  les  AVC  ischémiques,  les  embolies  systémiques,  les  accidents
ischémiques  transitoires,  les  hémorragies  intra-  et  extra-crâniennes,  les  AVC  hémorragiques,
les infarctus  du  myocarde  ainsi  que  les  décès.  La  population  étudiée  présente  les  mêmes  carac-
téristiques  que  celles  de  la  population  RE-LY.  Le  dabigatran  a  été  comparé  à  la  warfarin  en
condition expérimental  (trial-like  warfarin)  et  dans  la  vraie  vie  (real-world  prescribing)  Les
risques d’occurrence  des  événements  cliniques  sont  ceux  de  l’essai  RE-LY.  Les  coûts  associés
aux événements  ainsi  que  les  coûts  de  suivi  ont  été  calculés  à  partir  soit  des  tarifs  nationaux
franc¸ais, soit  de  la  littérature.  Le  nombre  d’événements  cliniques,  les  QALYs,  les  coûts  totaux
ainsi que  les  ratios  coût-efﬁcacité  incrémentaux  ont  été  calculés.
Résultats.  — Les  ratios  coût-efﬁcacité  incrémentaux  du  dabigatran  comparativement  aux  AVK,
en condition  expérimentale  et  dans  la  vraie  vie,  étaient,  respectivement,  de  15  838  D/QALY
et 7473  D/QALY.  Les  analyses  de  sensibilité  déterministes  et  probabilistes  montrent  que  ces
ratios sont  robustes  à  l’incertitude  et  la  variabilité  des  paramètres  du  modèle.  Le  ratio  coût-
efﬁcacité incrémental  du  dabigatran  est  en  dessous  de  24  000  D/QALY  et  36  000  D/QALY  dans
respectivement  71  %  et  92  %  des  simulations  en  contexte  expérimental  et  dans,  respectivement,
100 %  et  100  %  des  simulations  dans  la  vraie  vie.
Conclusion.  —  L’utilisation  du  dabigatran  chez  des  patients  franc¸ais  avec  une  ﬁbrillation  auric-
ulaire est  coût-effective  selon  les  seuils  couramment  acceptés.
© 2014  Elsevier  Masson  SAS.  Tous  droits  réservés.
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trial  ﬁbrillation  (AF)  is  the  most  common  arrhythmia  in
rance.  The  incidence  increases  with  age,  and  10%  of  peo-
le  over  80  years  of  age  have  the  condition  [1].  AF  is  the
ain  cause  of  stroke,  and  as  strokes  in  AF  patients  are  par-
icularly  severe  and  disabling,  their  prevention  is  of  great
mportance  [2,3].  Vitamin  K  antagonists  (VKAs)  and  aspirin
re  presently  the  main  preventive  agents  [4].  VKAs  have
een  shown  to  reduce  the  risk  of  stroke  by  68%  compared
ith  aspirin  [5],  but  have  a  narrow  therapeutic  window  of
f
2
inticoagulation  and  have  many  interactions  with  food  and
ther  drugs.  If  overdosed,  VKA  administration  presents  an
xcess  risk  of  hemorrhage,  while  protection  from  stroke  is
iminished  in  case  of  underdosing.  Thus,  VKAs  require  regu-
ar  international  normalized  ratio  (INR)  monitoring  and  dose
djustments  to  be  effective  and  safe.
Dabigatran  is  an  oral  direct  thrombin  inhibitor  that  pro-
ides  stable  anticoagulation  with  a ﬁxed  dose  and  no  need
or  anticoagulation  monitoring.  It  has  been  marketed  since
008  for  the  prevention  of  venous  thromboembolic  events
n  patients  undergoing  scheduled  surgery  for  total  knee  or
383
Figure 1. Simpliﬁed Markov model diagram. 1. Stroke history was
tracked in the model but is not depicted in the diagram. 2. Discon-
tinuations due to non-major bleed events. AMI: acute myocardial
infarction; DL: disability level deﬁned by modiﬁed Rankin Score
or Glasgow Outcomes Scale; ECH: extracranial hemorrhage; HS:
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hip  replacement.  The  RE-LY  study  [6,7]  demonstrated  that
dabigatran  is  effective  in  the  prevention  of  thromboembolic
events  in  patients  with  AF.  It  compared  two  doses  of  dabi-
gatran  (110  or  150  mg  twice  daily  [bid])  to  warfarin  (dosage
adjusted  on  INR).  It  demonstrated  that  the  rates  of  stroke
and  systemic  embolism  were  similar  (110  mg  bid)  or  lower
(150  mg  bid)  than  those  observed  in  patients  treated  with
warfarin.  The  risk  of  major  hemorrhage  was  similar  (150  mg
bid)  or  lower  (110  mg  bid).  Although  both  doses  of  dabiga-
tran  have  been  approved,  the  higher  dose  is  recommended
for  patients  <  80  years  old  and  the  lower  dose  for  patients
aged  ≥  80  years  [8].
The  aim  of  the  present  study  was  to  assess  the  cost-
effectiveness  of  dabigatran  compared  with  VKAs  in  patients
with  AF  using  a  Markov  model.  Following  the  recommenda-
tions,  the  model  evaluated  dabigatran  150  and  110  mg  bid
doses  for  patients  aged  <  80  and  ≥  80  years,  respectively.
Methods
Patient population
We  considered  a  cohort  of  10,000  patients  with  AF  followed
for  their  remaining  lifetime  to  capture  the  lifelong  conse-
quences  of  stroke  and  hemorrhage.  The  population  matched
the  criteria  of  the  RE-LY  trial  [6,7].  Patients  had  diagnosed
AF  and  at  least  one  of  the  following  characteristics:  at  least
one  additional  risk  factor  for  stroke  or  embolism  (as  deﬁned
by  the  CHADS2 score  risk  stratiﬁcation  scheme)  or  impaired
left  ventricular  ejection  fraction.  They  were  eligible  for
anticoagulation  treatment  but  were  not  taking  concomitant
anticoagulation  treatment.  The  CHADS2 score  ranged  from  0
to  6  (mean  2.1).  Twenty  percent  of  patients  had  a  history  of
previous  stroke  or  transient  ischemic  attack.  The  mean  age
of  the  patients  was  69  years  and  65%  were  men.
Model structure
The  model  is  an  adaptation  of  Sorensen  et  al.’s  cost-
effectiveness  model  to  the  French  setting.  It  has  been  fully
described  elsewhere  [9,10].  The  cost-effectiveness  of  dabi-
gatran  was  modeled  with  a  3-month  cycle  Markov  model.
The  different  events  taken  into  account  were:  ischemic
stroke,  intracranial  hemorrhage,  hemorrhagic  stroke  (all
fatal,  independent,  moderate  disability  and  totally  depend-
ent);  systemic  embolism,  extracranial  hemorrhage,  acute
myocardial  infarction  (all  fatal  and  non-fatal);  transient
ischemic  attack  and  death  from  other  causes.  At  each  cycle
of  the  model,  patients  could  experience  one  of  the  pre-
cited  clinical  events  or  remain  unchanged  in  their  current
health  state.  A  3-month  cycle  length  was  used  because  it
is  unlikely  that  patients  would  experience  more  than  one
major  event  during  any  3-month  period.  The  consequences
of  the  clinical  events  were  disability  as  deﬁned  by  the  modi-
ﬁed  Rankin  Score  (after  a  stroke)  or  Glasgow  Outcomes  Scale
(after  intracranial  hemorrhage),  death,  reduction  in  qual-
ity  of  life,  changes  in  risks  of  future  events  and  treatment
status.
Fig.  1  presents  a  simpliﬁcation  of  the  Markov  model.
Severe  hemorrhagic  events  could  result  in  discontinuation
of  current  treatment  and  a  switch  to  aspirin.  Patients  could
u
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nemorrhagic stroke; ICH: intracranial hemorrhage; SE: systemic
mbolism; IS: ischemic stroke; TIA: transient ischemic attack.
lso  discontinue  for  other  reasons,  clinical  or  not.  A  ﬁrst
ver  stroke  resulted  in  an  increase  of  the  CHADS2 score  of
wo  points.  The  score  remained  unchanged  after  a  recurrent
troke.  It  increased  by  one  point  when  patients  passed  the
ge  of  75  years.  The  risk  of  extracranial  hemorrhage  doubled
hen  patients  passed  70  years  of  age  [11].
The  model  assumed  that  patients  not  discontinuing
emained  adherent  to  anticoagulation  treatment  and  the
elative  treatment  effect  remained  constant  over  time.
atients  discontinuing  treatment  received  no  further  clinical
eneﬁt.
Future  costs  and  outcomes  were  discounted  at  4%  per
nnum  to  convert  them  to  present  day  equivalents  accord-
ng  to  the  recommendations  of  the  Haute  Autorité  de  santé
HAS;  the  French  National  Authority  of  Health)  [12].
odel scenarios
n  RE-LY,  64%  of  patients  under  VKAs  were  at  their  INR  tar-
et,  whereas  in  France,  published  data  showed  that  only
6%  are  at  target  [13].  Moreover,  two  other  publications
14,15]  have  suggested  that  patients  presenting  similar  pro-
les  to  RE-LY  patients  with  AF  received  other  anticoagulant
gent  than  VKAs  or  were  not  treated,  leading  to  less  efﬁ-
acious  stroke  prevention.  For  this  reason,  we  modeled  two
cenarios:  a  ‘‘trial-like’’  scenario  (where  patients  received
abigatran  or  warfarin)  and  a  ‘‘real-life’’  scenario  (where
atients  received  dabigatran,  a  VKA,  aspirin  or  no  anticoag-
lant).  In  the  ‘‘real-life’’  scenario,  the  relative  efﬁcacy  of
abigatran  versus  VKAs  was  the  same  as  in  the  RE-LY  trial
nd  was  derived  from  indirect  comparisons  with  aspirin  or
o  treatment  [16]. The  percentages  of  patients  taking  VKAs,
3a
w
s
D
P
A
a
a
m
o
R
u
p
R
F
c
U
S
u
d
e
t
e
s
T
f
p
p
R
T
e
t
N
h
b
f
t
f
d
d
h
m
t
a
i
m
b
o
[
D
q
r
r
t
F
a
o
m
a
h
D
t
A
H
a
t
t
p
I
D
D
c
a
d
s
t
s
f
f
t
N
d
a
S
r
i
F
t
w
s
c
D
i
d
d
m
p
r
t
a
T
m
D
f
p
d
D84  
spirin  or  untreated  were  derived  from  Cohen  et  al.  [15],
hile  data  from  Cegedim  Strategic  Data  [14]  were  used  in  a
ensitivity  analysis.
ata sources
robabilities  of  events
nnual  probabilities  of  events  in  the  VKA  arm  and  the  rel-
tive  risks  (RRs)  of  dabigatran  110  and  150  mg  bid,  aspirin
nd  no  treatment  versus  VKAs  were  taken  from  the  original
odel  [9].  All-cause  mortality  data  adjusted  for  age  were
btained  from  the  French  Institute  of  Health  and  Medical
esearch  [17].  Baseline  characteristics  of  the  patient  pop-
lation  in  the  model  matched  the  CHADS2 distribution  of
atients  entering  into  the  model  was  the  same  as  observed  in
E-LY.  Because  ﬂuindione  is  the  most  frequently  used  VKA  in
rance,  we  assumed  that  outcomes  from  RE-LY  with  warfarin
ould  be  transposed.
tilities
ince  no  utility  values  were  available  in  the  French  context,
tility  values  for  each  disability  level  and  utility  decrements
ue  to  clinical  events  were  taken  from  the  published  lit-
rature  [18,19].  The  effective  decreases  in  utility  at  the
ime  of  the  event  were  0.139  for  stroke,  0.120  for  systemic
mbolism,  0.181  for  intracranial  hemorrhage,  0.103  for  tran-
ient  ischemic  attack  and  0.125  for  myocardial  infarction.
he  level  of  impairment  corresponding  to  the  patient’s
unctional  status  was  also  included:  0.65  for  independent
atients  with  stroke  history,  0.46  for  moderately  dependent
atients  and  0.30  for  totally  dependent  patients.
esource  use  and  costs
he  baseline  scenario  considered  only  direct  medical
xpenditures  covered  by  the  National  Sickness  Fund  (NSF),
hus  adopting  a  health  services  payer  perspective.  The
SF  covers  all  healthcare  services  expenditures  (acute
ospital  care,  ambulatory  services,  drug  treatment,  reha-
ilitation  and  healthcare  delivered  in  ‘‘nursing  home’’-type
acilities.  The  French  ‘‘départements’’  (France  is  adminis-
ratively  divided  into  96  ‘‘départements’’)  are  responsible
or  partially  covering  expenditures  related  to  functional
ependency  of  patients,  through  payments  adjusted  on  the
egree  of  dependency.  Finally,  in  nursing  homes,  patients
ave  to  pay  out-of-pocket  accommodation.  HAS  recom-
ends  that  all  direct  expenses  by  all  potential  payers  are
aken  into  account  when  performing  a  cost-effectiveness
nalysis,  therefore,  a  secondary  scenario  was  considered
ncluding  payments  from  the  social  services  of  the  depart-
ents  and  out-of-pocket  money  from  patients.  All  costs  have
een  updated  to  the  year  2011  according  to  the  price  index
f  medical  services.  All  costs  are  summarized  in  Table  1
20—24].
irect  medical  expenditures
Anticoagulation  treatment  costs.  The  most  fre-uently  prescribed  VKA  in  France  is  ﬂuindione  with  a
ecommended  dose  of  1  pill  per  day.  Based  on  the  French
egister  of  pharmaceutical  specialities,  Vidal,  the  daily
reatment  cost  of  ﬂuindione  was  D0.13.
m
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The  tariff  for  INR  monitoring  was  obtained  from  the
rench  NSF  website  [21]  and  was  D14.04.  This  rate  was
djusted  to  take  into  consideration  the  fact  that  in  one-third
f  cases,  the  INR  would  be  included  in  a  bundled  rate  for
ultiple  blood  parameter  testing,  thus  at  a cheaper  rate;
nd  in  two-ﬁfths  of  cases,  the  test  would  require  a  nurse
ome  visit  for  the  blood  sample.  A  ﬁnal  adjusted  unit  cost  of
11.17  was  applied.  The  annual  cost  of  treatment  with  a  VKA
herefore  reached  D181.49  (i.e.  365  ×  0.13  D  +  12  ×  11.17  D).
ccording  to  the  French  National  Agency  for  Medicines  and
ealth  Products  Safety  [13],  French  patients  under  VKAs
re  out  of  target  INR  54%  of  the  time,  which  suggests  that
hey  may  require  more  INR  tests  to  adjust  the  posology.  In
he  one-way  sensitivity  analysis,  we  assumed  that,  in  real
ractice,  French  patients  would  require  at  least  six  more
NR  tests,  thus  leading  to  an  annual  cost  of  treatment  of
248.51  (i.e.  365  ×  0.13  D  +  18  ×  11.17  D).
The  daily  cost  for  dabigatran  110  or  150  mg  bid  was
2.53  (Table  1).  No  monitoring  costs  were  considered.  In  the
ase  of  AF,  the  European  Society  of  Cardiology  recommends
spirin  [25]  if  VKAs  are  not  tolerated.  We  assumed  a  325  mg
aily  dose.  Based  on  the  French  register  of  pharmaceutical
pecialities,  Vidal,  the  daily  cost  of  this  dosage  was  D0.09.
Costs  associated  with  stroke.  Stroke  costs  comprised
wo  major  items:  the  cost  of  initial  hospitalization  and
ubsequent  costs,  distinguishing  the  ﬁrst  year  after  stroke
rom  following  years.  The  number  of  initial  hospitalizations
or  stroke  and  the  diagnosis-related  group  (DRG)  in  which
hey  were  classiﬁed  were  selected  from  the  French  2009
ational  Hospital  Database  (Programme  de  médicalisation
es  systèmes  d’information  [PMSI]).  This  database  records
ll  admissions  to  public  and  private  hospitals  in  a  given  year.
tays  were  selected  on  their  main  diagnosis  based  on  10th
evision  of  the  ICD-10  codes:  hemorrhagic  stroke  (I60—I62),
schemic  stroke  (I63),  transient  ischemic  attack  (G45).  In  the
rench  classiﬁcation,  DRGs  are  split  into  four  levels  based  on
he  severity  of  comorbidities.  AF  is  a  level-2  comorbidity,  so
e  selected  only  DRGs  with  a minimum  level  of  two.  For  each
tay,  the  national  2011  tariff  of  the  DRG  was  applied:  the
osts  of  the  initial  hospitalization  were  D7108,  D7240  and
5429  for  ischemic  stroke,  hemorrhagic  stroke  and  transient
schemic  attack,  respectively  (Table  1).
Follow-up  costs  during  the  ﬁrst  year  after  stroke  were
erived  from  the  ECIC  study  [26]. In  this  study,  costs  were
ifferentiated  by  resulting  disability  level  (independent,
oderate  disability  and  totally  dependent)  18  months  after
atients  experienced  a  stroke.  Initial  hospitalization  costs
eported  in  that  study  were  not  taken  into  account,  since
hey  were  obtained  separately.  The  cost  was  calculated  rel-
tive  to  the  ﬁrst  12  months  and  included  nursing  home  care.
he  annual  mean  costs  of  independent  patients,  those  with
oderate  disability  and  dependent  patients  were  D4632,
14,015  and  D29,582,  respectively.
Follow-up  costs  in  subsequent  years  were  based  on  data
rom  Spieler  et  al.  [23]. The  direct  medical  costs  of  inde-
endent  patients,  those  with  moderate  disability  and  totally
ependent  patients  living  at  home  were  D233,  D369  and
719  per  month,  respectively.
Costs  associated  with  myocardial  infarction  or
ajor hemorrhage.  Only  the  cost  of  the  initial
ospitalization  was  taken  into  account.  The  initial  hospital-
zation  cost  was  calculated  using  2009  PMSI  (ATIH)  data  and
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Table  1  Costs  of  medication,  events  and  follow-up  after  a  stroke.
Cost  (D)  Source
Drug  costs  per  day  (public  prices)
Dabigatran  etexilate  2.53  [20]
Warfarin  (ﬂuindione)  0.13  [20]
Aspirin  0.09  [20]
Monitoring  costs  per  year
Monthly  INR  monitoring 134.04 [21]
Event  costs  per  year
Ischemic  stroke
Fatal  (initial  hospitalization)  7108  PMSI  + tariffs  2011
Independent  (including  initial  hospitalization)  11,740  PMSI  + tariffs  2011
Moderate  disability  (including  initial  hospitalization)  21,123  PMSI  + tariffs  2011
Totally  dependent  (including  initial  hospitalization)  36,690  PMSI  + tariffs  2011
Intracranial  hemorrhage  or  hemorrhagic  stroke  PMSI  + tariffs  2011
Fatal  (initial  hospitalization)  7240  PMSI  + tariffs  2011
Independent  (including  initial  hospitalization)  11,872  PMSI  + tariffs  2011
Moderate  disability  (including  initial  hospitalization)  21,255  PMSI  + tariffs  2011
Totally  dependent  (including  initial  hospitalization)  36,822  PMSI  + tariffs  2011
Systemic  embolism  or  transient  ischemic  attack  5429  PMSI  + tariffs  2011
Extracranial  hemorrhage  1550  PMSI  + tariffs  2011
Acute  myocardial  infarction  4860  PMSI  + tariffs  2011
Follow-up  costs  per  quarter
Independent  699  [23]
Moderate  disability  1107  [23]
Totally  dependent  2944  [23,24]
INR: International Normalized Ratio; PMSI: Programme de médicalisation des sytèmes d’information (French National Hospital Database).
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pthe  national  2011  tariff.  Stays  were  selected  when  the  main
diagnosis  was  that  of  myocardial  infarction  (ICD-10:  I21  and
I22)  or  major  hemorrhage  (K625,  K920,  K921,  K922,  R041,
R042,  R048,  R049,  R31  and  R58).  Only  DRGs  with  a  minimum
severity  level  of  two  were  selected.  The  resulting  cost  was
applied  to  each  event.
Cost  of  institutionalization.  After  they  experience
a  stroke,  dependent  patients  can  be  admitted  to  differ-
ent  settings:  long-term  care  unit  (unité  de  soins  longue
durée  [USLD]),  nursing  home  for  dependent  elderly  people
(Établissement  d’hébergement  pour  personnes  agées  dépen-
dantes  [EPHAD]),  specialized  centre  for  disabled  patients
(Maison  d’accueil  spécialisée)  or  residential  care  home
(Foyer  d’accueil  médicalisé).  USLDs  and  EPHADs  provide
the  same  services  and,  according  to  the  French  Ministry
of  Health  statistics  [27],  represent  93.1%  of  all  admissions.
Thus,  EPHADs  and  USLD  are  the  dominant  setting  and  we
used  tariffs  and  costing  information  available  for  these  sett-
ings,  although  they  are  less  costly  than  the  two  other,  more
specialized  settings.
USLDs  and  EPHADs  are  ﬁnanced  through  a  daily  rate  for
healthcare  services,  covering  physician  and  nursing  care
costs  and  funded  by  the  NSF.  There  is  a  daily  rate  to  pay
for  the  burden  of  dependency  of  elderly  people,  funded  by
the  social  budget  of  departments,  and  one  for  accommoda-
tion,  paid  by  the  residents.  In  the  absence  of  national  data
sources  on  actual  tariffs  for  different  settings,  we  used  sur-
vey  data  [24],  which  provide  costs  for  the  ﬁrst  two  ﬁnancing
sources.  The  mean  cost  for  healthcare  services  was  D24.50
a
m
a
ter  day  (range  D19.90—29.20).  The  mean  expenditure  of
epartments  was  D12.70  per  day  (range  D11.30—13.30)  [24].
ccording  to  the  Inspectorate  General  for  Social  Affairs  [28],
ut-of  pocket  charges  for  patients  in  EPHADs  was  D60.00  per
ay  (range  D50.00—97.70).
Using  existing  sources  [29,30],  we  estimated  that  35.2%
f  post-stroke  dependent  patients  were  admitted  into  a
ursing  home.  Thus,  the  extra  cost  of  D24.50  per  day  for
ealthcare  services  was  added  to  other  direct  medical  costs
n  the  same  proportion.  The  costs  to  cover  dependency  and
he  out-of-pocket  costs  for  patients  were  included  in  the
ll-payer  analysis  (D72.70  per  day).
Analyses.  The  base-case  model  compared  dabigatran
o  ‘‘trial-like’’  warfarin  use.  Model  outcomes  were  the  num-
er  of  events,  quality-adjusted  life  years  (QALYs),  total  costs
nd  incremental  cost-effectiveness  ratios  (ICERs).
One-way  sensitivity  analyses  were  computed  on  the  base-
ase  to  identify  key  determinants  of  cost-effectiveness  by
arying  parameters  individually.  A  probabilistic  sensitivity
nalysis  was  conducted  to  compute  a  cost-effectiveness
cceptability  curve.  The  cumulative  effect  of  varying  all
odel  parameters  within  their  statistical  distributions,
ased  on  95%  conﬁdence  intervals,  was  tested.  For  this
nalysis,  1000  trials  were  run,  where  each  input  was  sam-
led  at  random  from  probability  distribution  functions
ssigned  to  each  variable.  Distributions  were  deﬁned  by
eans  and  reported  or  calculated  standard  errors.  We
ssumed  that  probabilities  and  utilities  had  beta  distribu-
ions  (bounded  between  0  and  1)  and  relative  risks  (RRs)  had
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og-normal  distributions  and  event  costs  had  gamma  distri-
utions  (bounded  by  0  with  a  right  skew)  [31].  The  model
as  computed  in  Microsoft  Excel  2003.
Cost-effectiveness  thresholds.  Thresholds  of
24,000  and  D36,000  were  selected  based  on  the  published
hresholds  of  £20,000  and  £30,000  in  the  United  Kingdom
32],  since  there  is  no  deﬁned  threshold  in  France.  We
pdated  the  conversion  of  the  UK  threshold  using  the
xchange  rate  of  £0.827  to  1  D  observed  on  March  2014  and
ounded  the  conversion  results.
esults
ase-case analysis
ompared  with  ‘‘trial-like’’  warfarin,  patients  treated  with
abigatran  were  predicted  to  experience  fewer  ischemic
trokes,  systemic  embolisms,  transient  ischemic  attacks
nd  intracranial  hemorrhages  or  hemorrhagic  strokes,  but
ore  extracranial  hemorrhage  and  myocardial  infarctions
Table  2).
Compared  with  ‘‘real-world’’  prescribing,  patients
reated  with  dabigatran  were  predicted  to  experience  fewer
schemic  strokes,  systemic  embolism,  transient  ischemic
ttacks,  intracranial  hemorrhage  or  hemorrhagic  strokes  and
xtracranial  hemorrhage,  but  more  myocardial  infarctions
Table  2).
These  differences  in  the  numbers  of  clinical  events
esulted  in  an  increase  in  QALYs  for  patients  treated  with
abigatran  (7.94)  versus  ‘‘trial-like’’  warfarin  (7.70)  and
‘real-world’’  prescribing  (7.56).  The  results  are  presented
n  Table  3,  along  with  detailed  costs  and  ICERs  for  the  dif-
erent  scenarios.  Follow-up  costs  represented  the  largest
hare  of  the  costs  (47%  for  dabigatran;  62%  for  ‘‘trial-
ike’’  warfarin  and  ‘‘real-world’’  prescribing).The  ‘‘payer
erspective’’  ICERs  for  dabigatran  versus  ‘‘trial-like’’  war-
arin  and  ‘‘real-world’’  prescribing  were  D15,838/QALY  and
u
1
i
o
igure 2. One-way sensitivity analysis, which represents the effect of
cenario). CI: conﬁdence interval; ICER: incremental cost-effectiveness 
ife year; RR: relative risk.J.  Chevalier  et  al.
7473/QALY,  respectively  (Table  3).  Considering  the  ‘‘all-
ayer  perspective,’’  these  ﬁgures  were  D13,568/QALY  and
5663/QALY,  respectively.
ne-way sensitivity analyses
he  most  inﬂuential  variables  in  our  model  (payer  perspec-
ive,  ‘‘trial-like’’  warfarin)  were  the  RR  of  ischemic  stroke
ith  dabigatran  and  the  time  horizon  of  the  model  (Fig.  2).
sing  a  shorter  time  horizon  of  10  years  increased  the  ICER
o  D33,145/QALY.  To  a  lesser  extent,  the  RRs  of  intracranial
emorrhage  and  hemorrhagic  stroke,  the  discounting  rate
nd  warfarin  monitoring  cost  also  affected  the  ICER  (Fig.  2).
nly  the  variables  with  the  greatest  ability  to  inﬂuence  the
esults  are  presented  in  Fig.  2.
The  impact  of  the  proportion  of  different  treatments  in
he  ‘‘real-world  prescribing’’  scenario  was  also  tested,  com-
aring  the  proportions  observed  in  Cohen  et  al.  [15]  (VKA:
8.7%;  aspirin:  20.7%;  no  treatment:  0.6%)  to  those  observed
n  Cegedim  Strategic  Data  [14]  (VKA:  59%;  aspirin:  22%;  no
reatment:  19%).  Increasing  the  number  of  patients  with  no
reatment  and  decreasing  the  number  of  patients  treated
y  VKAs  provided  a  slightly  more  favorable  ICER  (D4863  vs
7473/QALY).
robabilistic sensitivity analysis
he  results  of  the  probabilistic  sensitivity  analysis  showed
hat  the  ICER  of  dabigatran  was  <  D24,000  in  71%  of  the  sim-
lations  when  compared  with  ‘‘trial-like’’  warfarin  and  in
00%  of  cases  when  compared  with  ‘‘real-world’’  prescrib-
ng  (Fig.  3).  It  was  <  D36,000  in  92%  and100%,  respectively,
f  simulations.
 varying key model parameters on the ICER (‘‘trial-like’’ warfarin
ratio; INR: International Normalized Ratio; QALY: quality-adjusted
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Table  2  Clinical  events  per  100  patient-years.
Clinical  events  Dabigatran  ‘‘Trial-like’’
warfarin
‘‘Real-world’’
prescribing
Ischemic  stroke  (primary  +  recurrent)  4.49  4.65  5.32
Fatal  1.71  1.70  1.96
Independent  1.49  1.66  1.87
Moderate  disability 0.78  0.72  0.83
Totally  dependent 0.51 0.57 0.66
Systemic  embolism 0.54 0.59 0.71
Fatal  0.002  0.003  0.003
Non-fatal  0.53  0.59  0.71
Transient  ischemic  attack  1.35  1.60  1.72
Intracranial  hemorrhage  or  hemorrhagic  stroke  0.50  1.12  1.07
Fatal  0.21  0.53  0.47
Independent  0.05  0.10  0.10
Moderate  disability  0.06  0.11  0.11
Totally  dependent  0.18  0.38  0.38
Extracranial  hemorrhage  4.50  4.00  4.70
Fatal  0.05  0.05  0.06
Non-fatal,  non-gastrointestinal  3.49  3.24  3.81
Non-fatal,  gastrointestinal  0.96  0.71  0.83
Acute  myocardial  infarction  1.47  1.21  1.30
Fatal  0.02  0.01  0.02
1.46
p
l
w
iNon-fatal  
Discussion
This  modeling  study  evaluated  the  cost-effectiveness
of  dabigatran  compared  with  ‘‘trial-like’’  warfarin  and
‘‘real-world’’  prescribing,  using  dabigatran  150  mg  bid
for  patients  <  80  years  of  age  and  110  mg  bid  for
patients  aged  ≥  80  years.  In  the  base-case  scenario  (payer
o
o
i
Table  3  Life-time  model  results  (costs,  in  D  per  patient):  pay
Per  patient  Drug
costs
Even
costs
Payer  perspective
Dabigatran  vs  ‘‘trial-like’’  warfarin
Dabigatran  6994  5250
‘‘Trial-like’’  warfarin  1395  5981
Difference  5599  —731
Dabigatran  vs  ‘‘real-world  prescribing’’
Dabigatran  6994  550  
‘‘Real-world’’  prescribing 1196  6677
Difference  5798  —142
‘‘All-payer’’  perspective
Dabigatran  vs  ‘‘trial-like’’  warfarin
Dabigatran  6994  4866
‘‘Trial-like’’  warfarin  1395  5440
Difference  5599  —574
Dabigatran  vs  ‘‘real-world’’  prescribing
Dabigatran  6994  4866
‘‘Real-world’’  prescribing  1196  6082
Difference  5798  —121
ICER: incremental cost-effectiveness ratio; QALY: quality-adjusted life  1.19  1.44
erspective),  the  ICER  of  dabigatran  compared  with  ‘‘trial-
ike’’  warfarin  was  D15,838/QALY;  this  fell  to  D7473/QALY
hen  dabigatran  was  compared  with  ‘‘real-world’’  prescrib-
ng.  In  this  latter  case,  the  relative  clinical  effectiveness
f  dabigatran  was  enhanced  because  a  signiﬁcant  number
f  patients  did  not  receive  adequate  anticoagulation,  thus
ncurring  higher  risks  than  those  observed  in  RE-LY.  When  an
er  and  ‘‘all-payer’’  perspectives.  1.
t Follow-up
costs
Total
costs
Total
QALYs
ICER
 10,987  23,231  7.94  15,838
 12,021  19,397  7.70
 1034  3934  0.24
10,987  23,231  7.94  7473
 12,485  20,358  7.56
7  —1498  2873  0.38
 12,403  24,263  7.94  13,568
 14,143  20,978  7.70
 —1740  3285  0.24
 12,403  24,263  7.94  5663
 14,808  22,086  7.56
6  —2405  2177  0.38
year.
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Aigure 3. Cost-effectiveness acceptability curve of dabigatran
ersus ‘‘trial-like’’ warfarin and ‘‘real-world’’ prescribing.
‘all-payer’’  perspective  was  adopted,  the  ICERs  were  even
ore  favorable:  each  ICERs  was  decreased  by  approximately
000  D/QALY.
We  have  compared  our  results  to  published  cost-
ffectiveness  studies  in  other  countries.  Twelve  studies  with
ingle  technology  assessments  of  dabigatran  compared  with
KAs  covering  eight  countries  were  identiﬁed  in  PubMed.
mong  these,  six  studies  [33—38]  adapted  the  model  from
orensen  et  al.  [10]  and  assessed  the  cost-effectiveness
f  dabigatran  150  or  110  mg  bid  according  to  age.  The
ther  studies  assessed  different  treatment  courses,  includ-
ng  assessing  150  and  110  mg  bid  separately,  comparing
abigatran  to  warfarin,  aspirin  and  clopidogrel,  or  focus-
ng  on  sub-groups  based  on  age  or  risk  level  measured  by
HADS2 score  [39—43].
A  brief  comparison  of  the  studies  showed  higher  ICERs
n  studies  from  USA  (from  D9364/QALY  for  150  mg  bid  com-
ared  with  warfarin  [39,40]  to  D113,400/QALY  for  110  mg
id  compared  with  warfarin  [43]).  A  major  differentiat-
ng  factor  was  the  daily  price  of  dabigatran,  which  ranged
rom  D5.20  to  D7.20  in  USA  studies  [39,41]  and  from  D2.45
Canada:  ICER  =  D13,987/QALY  [10])  to  D3.20  (Switzerland:
CER  =  D8213/QALY  [37])  in  other  countries.  ICERs  for  studies
hat  based  dabigatran  dose  on  age  and  were  based  on  trial
ata  and  had  similar  costing  methods  ranged  from  D6002
er  QALY  in  UK  [35]  to  D17,581  per  QALY  in  Spain  [34]. Thus,
ur  results  in  France  are  in  the  range  of  the  results  found  in
ther  European  countries.  The  two  main  economic  factors
hat  contributed  to  such  variability  were,  ﬁrstly,  the  cost  of
reatment  with  dabigatran  relative  to  the  cost  of  monitor-
ng  INRs  with  VKAs  and,  secondly,  the  relative  costs  of  stroke
nd  prevention.
tudy limitations
he  study  was  based  on  the  only  available  published  clinical
rial  comparing  dabigatran  with  warfarin.  We  assumed  that
uindione  would  have  similar  efﬁcacy  to  warfarin  in  a  com-
arative  trial  with  dabigatran.  To  cope  with  both  of  these
imitations,  we  used  a  deterministic  (one-way)  analysis  and
T
o
mJ.  Chevalier  et  al.
 probabilistic  sensitivity  analysis,  which  showed  that  these
CERs  were  robust  to  uncertainty  and  variability  in  the  model
arameters,  including  outcomes.  Assuming  a  willingness-to-
ay  threshold  of  around  D24,000,  the  ICERs  were  below  this
hreshold  in  all  but  the  most  conservative  scenarios  against
abigatran  (i.e.  short  time  horizon  and  upper  limit  of  the
5%  conﬁdence  intervals  for  RRs  of  ischemic  stroke  and
ntracranial  hemorrhage).  Nevertheless,  the  certainty  with
hich  dabigatran  was  judged  to  be  cost-effective  appeared
t  acceptable  levels,  with  71%  and  100%  of  simulations  for
‘trial-like’’  warfarin  and  ‘‘real-world’’  prescribing,  respec-
ively,  below  the  D24,000  threshold,  and  92%  and  100%,
espectively,  below  the  D36,000  threshold.
Results  are  particularly  sensitive  to  the  cost  of  moni-
oring  patients  treated  with  VKAs.  In  France,  the  overall
erformance  in  general  practice  is  low  when  compared  with
onitoring  in  the  RE-LY  trial.  Thus,  an  important  issue  is
ow  much  investment  is  needed  in  France  to  get  closer  to
ptimal  management,  which  would  increase  the  total  cost  of
KA  treatment  but  also  its  effectiveness.  Moreover,  in  real
ife,  compliance  issues  may  arise  with  dabigatran  because
f  twice  daily  administration  and  the  absence  of  monitor-
ng.  Also,  we  have  not  included  costs  of  follow-up  post-acute
yocardial  infarction  in  the  model,  which  results  in  improv-
ng  the  ICER  for  dabigatran  because  of  an  excess  event  rate
ith  this  treatment.  However,  the  rate  of  acute  myocardial
nfarction  is  a  third  the  rate  of  strokes  and  this  has  a  limited
mpact  on  the  ICER.
We  also  assumed  that  treatment  efﬁcacy  was  sustained
eyond  the  trial  period,  as  there  is  no  evidence  that  the  efﬁ-
acy  of  anticoagulation  would  change  in  adherent  patients.
e  used  dropout  rates  from  RE-LY  for  both  treatments,
hich  may  prove  to  be  untrue  in  real  life.  Finally,  our  esti-
ation  of  the  cost  of  dependent  patients  in  nursing  homes
s  not  based  on  observed  resource  use;  it  may  be  underesti-
ated,  since  we  have  focused  only  on  the  ones  with  the  less
ntensive  care  for  handicapped  patients.
onclusion
his  modeling  study  suggests  that  the  use  of  dabigatran  for
troke  prevention  in  French  AF  patients  is  likely  to  be  cost-
ffective  according  to  usually  accepted  thresholds.
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